Obviousness

Obviousness Analysis under 35 U.S.C. § 103

A patent claim is obvious under 35 U.S.C. § 103 if the differences between the claimed invention and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art (POSA). This analysis considers what a POSA would have been motivated to combine or modify existing prior art to arrive at the claimed invention, with a reasonable expectation of success.

The priority date of US Patent 12370153 is July 12, 2023 [cite: Prior art date 2023-07-12]. Therefore, any prior art publicly available before this date can be considered.

Independent Claim 1 Analysis:

Claim 1 covers a ready-to-use, sterile ketamine product comprising an aqueous ketamine solution (0.5 to 2.5 mg/mL), a tonicity adjusting agent, a pH adjusting agent, and water for injection, notably free of benzethonium chloride. [cite: Claim 1]

Combination of Prior Art References:

A strong argument for obviousness of Claim 1 can be made by combining the teachings of Biomed (New Zealand data sheet, June 15, 2021) and Ketalar (FDA label), potentially supplemented by general knowledge in the art as represented in references like Remington's Pharmaceutical Sciences.

1. Biomed (New Zealand data sheet, June 15, 2021):

   • Biomed discloses a "ready-to-use" 100 mg/100 mL (1 mg/mL) ketamine solution for infusion packaged in a flexible IV bag with an overwrap.
   • The solution contains sodium chloride as a tonicity adjusting agent.
   • It is explicitly described as "preservative-free."
   • It has a pH of 3.5-5.5.
   • It has a shelf-life of 24 months when stored at or below 25°C.
   • The petitioner in PGR2026-00036 argued that Biomed discloses every limitation of challenged independent and dependent claims, including concentration, composition, pH, sterility, RTU status, and shelf-life. They further contended that other claimed features, such as the osmolality of 270-330 mOsmol/kg and chemical stability, were inherent properties of Biomed's isotonic, stable formulation.

2. Ketalar (FDA label):

   • Ketalar is a commercially available ketamine hydrochloride injection, formulated as a slightly acidic (pH 3.5-5.5) sterile solution.
   • It comes in concentrations of 10, 50, or 100 mg ketamine base per milliliter.
   • It explicitly states that it "contains not more than 0.1 mg/mL Phemerol® (benzethonium chloride) added as a preservative."
   • The label describes dilution instructions to prepare solutions containing 1 mg/mL or 2 mg/mL ketamine for intravenous infusion using 5% Dextrose Injection, USP or Sodium Chloride (0.9%) Injection, USP.

Motivation to Combine and Expectation of Success:

A POSA, at the time of the invention, would have been motivated to combine the teachings of Biomed and Ketalar for several reasons:

• Desire for preservative-free, ready-to-use formulations: The background of US12370153 explicitly states a need for "sterile, ready to use infusion container comprising a shelf-stable, liquid formulation of ketamine that does not contain a preservative or antimicrobial such as benzethonium chloride." This demonstrates a recognized problem in the art regarding the undesirability of benzethonium chloride due to its known toxicity. NRx Pharmaceuticals also filed a Citizen Petition with the FDA seeking removal of benzethonium chloride from ketamine products due to its toxicity.
• Existing dilution practices: Ketalar's instructions for diluting concentrated ketamine vials (e.g., 50 mg/mL or 100 mg/mL) to 1 mg/mL or 2 mg/mL in saline or dextrose for IV infusion clearly show that the desired final concentrations for administration were already known and practiced.
• Convenience and safety of ready-to-use: The inventors of US12370153 themselves state that "premixed formulations therefore avoid the cost, inconvenience, and risk of contamination or overdose that can be associated with reconstituting or diluting a concentrated ketamine formulation prior to administration to a patient." This motivation to provide ready-to-use formulations to minimize preparation errors and contamination is a well-known objective in pharmaceutical compounding.
• Biomed as a direct example: Biomed directly teaches a "ready-to-use," "preservative-free" ketamine solution at a concentration of 1 mg/mL, with an appropriate pH and tonicity, packaged in an IV bag, and having a long shelf-life. A POSA, aware of the toxicity concerns of benzethonium chloride in Ketalar, would look for ways to achieve a ready-to-use, preservative-free version of the commonly administered concentrations. Biomed provides exactly this.
• Terminal Sterilization: The PGR petition argues that for claims requiring specific sterilization methods (e.g., "terminally sterilized" in claim 2), general pharmaceutical knowledge (e.g., from "Remington 2021") teaches that terminal sterilization and aseptic filling are standard, well-known, and obvious pathways for manufacturing sterile parenteral drug products. This suggests that achieving a sterile product without benzethonium chloride through terminal sterilization, once a stable preservative-free formulation (like Biomed's) is known, would be a predictable manufacturing choice. WO1994023711A1 also describes sterilizing sealed ampoules of ketamine at 121°C for 20 minutes.

Therefore, a POSA, motivated by the recognized problems of dilution errors and preservative toxicity, and the known advantages of ready-to-use formulations, would have found it obvious to combine the specific characteristics of the preservative-free, ready-to-use ketamine solution described in Biomed (concentration, tonicity agent, pH, absence of preservative, packaging in an IV bag, and shelf-life) with the widely known and desired administration concentrations (1-2 mg/mL) derived from diluting concentrated Ketalar. The expectation of success would be high given that Biomed already demonstrates the feasibility of a stable, preservative-free, ready-to-use ketamine solution.

Independent Claim 35 Analysis:

Claim 35 covers a preservative-free aqueous ketamine solution (0.5 to 2.5 mg/mL ketamine, tonicity adjusting agent, pH adjusting agent, and water for injection) contained in a terminally sterilized, ready-to-use infusion container. [cite: Claim 35]

Combination of Prior Art References:

Similar to Claim 1, the combination of Biomed (New Zealand data sheet, June 15, 2021) and general knowledge of terminal sterilization, as exemplified by references like Remington's Pharmaceutical Sciences or the practices described in WO1994023711A1, would render Claim 35 obvious.

1. Biomed (New Zealand data sheet, June 15, 2021):
   • As detailed above, Biomed provides a ready-to-use, preservative-free ketamine solution at relevant concentrations (1 mg/mL), with appropriate tonicity and pH, packaged in a flexible IV bag with an overwrap, and possessing a 24-month shelf-life. While Biomed doesn't explicitly state "terminally sterilized," it describes a "sterile" product. For a sterile, ready-to-use infusion product, terminal sterilization is a common and preferred method when feasible.
2. General Knowledge of Terminal Sterilization (e.g., Remington, WO1994023711A1, KETALAR ANDA #76-092):
   • Terminal sterilization (e.g., by autoclaving, steam, or heat) is a well-established and preferred method for sterilizing pharmaceutical products in their final sealed containers due to enhanced safety and reduced contamination risk.
   • The PGR petition explicitly states that "Remington 2021 taught these are the two standard, well-known, and obvious pathways for manufacturing any sterile parenteral drug product."
   • WO1994023711A1, a prior art document, describes sterile filtering a ketamine solution and then sterilizing the sealed ampoules at 121°C for 20 minutes, demonstrating the application of terminal sterilization to ketamine formulations.
   • The FDA approval for Ketamine Hydrochloride Injectable USP, 50 mg/mL in 10 mL vials (ANDA #76-092) from April 30, 2001, mentions "additional terminal sterilization validation on the 50 mg/mL, 10 mL package" to provide supportive information, indicating that terminal sterilization was a standard consideration for ketamine injections well before the priority date of US12370153.

Motivation to Combine and Expectation of Success:

A POSA would have been motivated to combine the features of Biomed with terminal sterilization for the following reasons:

• Established practice for sterile products: Terminal sterilization is a standard and often preferred method for achieving sterility in pharmaceutical products due to its robustness. Given Biomed's disclosure of a stable, preservative-free ketamine solution, a POSA would naturally consider applying terminal sterilization to this formulation to produce a sterile, ready-to-use product.
• Safety and convenience benefits: As discussed, terminal sterilization enhances safety by reducing contamination risks compared to aseptic filling alone. Combining this with the ready-to-use, preservative-free nature of the Biomed solution would further improve patient safety and convenience, addressing the recognized needs in the art.
• Known compatibility of ketamine with heat sterilization: Prior art, such as WO1994023711A1, explicitly demonstrates the use of heat sterilization (121°C for 20 minutes) for ketamine solutions. The present patent itself includes a thermal stress study on ketamine HCL injection subjected to autoclave cycles, with results shown in tables 22 and 23, suggesting that ketamine's stability under thermal stress was investigated and manageable. This would provide a POSA with a reasonable expectation of success that the preservative-free ketamine solution could withstand terminal sterilization.
• Elimination of toxic preservatives: The ongoing efforts to remove benzethonium chloride from ketamine products due to toxicity (as evidenced by NRx Pharmaceuticals' Citizen Petition and the general understanding of BZT's toxicity) would strongly motivate a POSA to find methods to produce sterile ketamine formulations without such preservatives. Terminal sterilization of a preservative-free formulation is a logical approach to achieving this goal.

Therefore, a POSA, aware of the benefits of ready-to-use formulations, the drawbacks of preservatives like benzethonium chloride, and the widespread practice and known methods of terminal sterilization for injectable drugs (including ketamine), would have found it obvious to terminally sterilize the preservative-free, ready-to-use ketamine solution described by Biomed in an infusion container. The stability of ketamine under heat sterilization conditions, as shown in the prior art, would provide a reasonable expectation of success.